Investor Overview

Corporate Profile

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

Stock Quote

(Common)
Price	Change	% Change	Volume

Previous Close	Today's Open	Intraday High	Intraday Low

Exchange: (US Dollar)
Mar 5, 2021 11:42 AM EST

Date	Title
02/26/21	2020 Annual Report 1.3 MB
01/11/21	J.P. Morgan Healthcare Conference Investor Presentation 2.6 MB
05/08/20	AtriCure CONVERGE Investor Presentation in Conjunction with HRS 2.9 MB
08/12/19	Acquisition of SentreHEART Overview 778.9 KB

Date	Title
03/02/21	AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference MASON, Ohio --(BUSINESS WIRE)--Mar. 2, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Oppenheimer 31 st Annual
02/23/21	AtriCure Reports Fourth Quarter 2020 and Full Year 2020 Financial Results MASON, Ohio --(BUSINESS WIRE)--Feb. 23, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter 2020 and full year 2020 financial results.
02/10/21	AtriCure to Participate at the SVB Leerink 10th Annual Global Healthcare Conference MASON, Ohio --(BUSINESS WIRE)--Feb. 10, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming SVB Leerink 10 th Annual
02/02/21	AtriCure to Announce Fourth Quarter and Full Year 2020 Financial Results MASON, Ohio --(BUSINESS WIRE)--Feb. 2, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2020 financial results on Tuesday,

More News >>

Date	Title
03/02/21	AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference MASON, Ohio --(BUSINESS WIRE)--Mar. 2, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Oppenheimer 31 st Annual
02/23/21	AtriCure Reports Fourth Quarter 2020 and Full Year 2020 Financial Results MASON, Ohio --(BUSINESS WIRE)--Feb. 23, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter 2020 and full year 2020 financial results.
02/10/21	AtriCure to Participate at the SVB Leerink 10th Annual Global Healthcare Conference MASON, Ohio --(BUSINESS WIRE)--Feb. 10, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming SVB Leerink 10 th Annual
02/02/21	AtriCure to Announce Fourth Quarter and Full Year 2020 Financial Results MASON, Ohio --(BUSINESS WIRE)--Feb. 2, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2020 financial results on Tuesday,

More National News >>

Date	Title
08/13/19	AtriCure Completes Acquisition of SentreHEART MASON, Ohio --(BUSINESS WIRE)--Aug. 13, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has completed its previously announced acquisition of SentreHEART, Inc.
08/28/18	AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial Landmark study is the first prospective, randomized study comparing the Convergent approach to endocardial catheter ablation in persistent and long-standing persistent atrial fibrillation patients MASON, Ohio --(BUSINESS WIRE)--Aug. 28, 2018-- AtriCure, Inc.
06/05/18	AtriCure and Baheal Group Establish Partnership and China Distribution Agreement Baheal will serve as the exclusive distribution partner for AtriCure products across China MASON, Ohio--(BUSINESS WIRE)--Jun. 5, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes...
04/25/17	AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide AtriClip is the most widely used device globally for left atrial appendage management MASON, Ohio --(BUSINESS WIRE)--Apr. 25, 2017-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it

More International News >>

Date	Title
03/16/21 1:10 PM EDT	AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference

More Events >>

Search form

Investor Overview

Corporate Profile

Stock Quote